Brief: LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data From Second Pivotal Trial Of TP-03 For The Treatment Of Demodex Blepharitis

LianBio

03/05/2022 13:43

May 3 (Reuters) - LianBio  LIAN.O :
    * LIANBIO PARTNER TARSUS PHARMACEUTICALS ANNOUNCES POSITIVE
TOPLINE DATA FROM SECOND PIVOTAL TRIAL OF TP-03 FOR THE
TREATMENT OF DEMODEX BLEPHARITIS
    * TARSUS PHARMACEUTICALS - TP-03 MET PRIMARY ENDPOINT AND
ALL
SECONDARY ENDPOINTS IN SATURN-2 PIVOTAL PHASE 3 TRIAL WITH A
FAVORABLE SAFETY PROFILE
    * TARSUS PHARMACEUTICALS - PLANS TO SUBMIT A NEW DRUG
APPLICATION
FOR TP-03 TO U.S. FDA IN SECOND HALF OF 2022

Source text for Eikon:  ID:nGNX9n5tNB 
Further company coverage:  LIAN.O